Cytogen (US) signs OncoScint partners:
This article was originally published in Clinica
Cytogen (US) has signed letters of intent with CIS bio international (France) and Faulding (Canada) to market the OncoScint CR/OV imaging agent for detecting colorectal and ovarian cancers. CIS bio will distribute OncoScint in Europe and countries excluding North America, while Faulding is to distribute the agent in Canada. OncoScint is already marketed in the US by Cytogen's nuclear oncology department and has marketing approval in 13 European countries. It was previously marketed in Europe by EuroCetus, which was acquired by Chiron.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.